Literature DB >> 6847176

Comparative activity of amantadine and ribavirin against influenza virus in vitro: possible clinical relevance.

M J Browne, M Y Moss, M R Boyd.   

Abstract

The activities of amantadine and ribavirin against influenza A viruses were compared against low-multiplicity (plaque inhibition) and high-multiplicity (protein synthesis inhibition) infections. Our results suggest that the predictive value of in vitro data for the clinic may be improved by consideration of tests against a high-multiplicity infection.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6847176      PMCID： PMC184681          DOI： 10.1128/AAC.23.3.503

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  Comparative clinical and laboratory evaluation of the prophylactic capacity of ribavirin, amantadine hydrochloride, and placebo in induced human influenza type A.

Authors:  A Cohen; Y Togo; R Khakoo; R Waldman; M Sigel
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

3.  Therapeutic effects of aerosolized amantadine in naturally acquired infection due to influenza A virus.

Authors:  F G Hayden; W J Hall; R G Douglas
Journal:  J Infect Dis       Date:  1980-05       Impact factor: 5.226

4.  Ribavirin small-particle aerosol treatment of influenza.

Authors:  V Knight; H W McClung; S Z Wilson; B K Waters; J M Quarles; R W Cameron; S E Greggs; J M Zerwas; R B Couch
Journal:  Lancet       Date:  1981-10-31       Impact factor: 79.321

5.  Lack of effect of oral ribavirin in naturally occurring influenza A virus (H1N1) infection.

Authors:  C B Smith; R P Charette; J P Fox; M K Cooney; C E Hall
Journal:  J Infect Dis       Date:  1980-05       Impact factor: 5.226

6.  Susceptibility of influenza A viruses to amantadine is influenced by the gene coding for M protein.

Authors:  M D Lubeck; J L Schulman; P Palese
Journal:  J Virol       Date:  1978-12       Impact factor: 5.103

7.  Clinical evaluation of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) in a double-blind study during an outbreak of influenza.

Authors:  F Salido-Rengell; H Nasser-Quinones; B Briseno-Garcia
Journal:  Ann N Y Acad Sci       Date:  1977-03-04       Impact factor: 5.691

8.  Mechanism and specificity of action of ribavirin.

Authors:  M J Browne
Journal:  Antimicrob Agents Chemother       Date:  1979-06       Impact factor: 5.191

9.  On the mechanism of inhibition of influenza virus replication by amantadine hydrochloride.

Authors:  J J Skehel; A J Hay; J A Armstrong
Journal:  J Gen Virol       Date:  1978-01       Impact factor: 3.891

10.  Amantadine-resistance as a genetic marker for influenza viruses.

Authors:  G Appleyard
Journal:  J Gen Virol       Date:  1977-08       Impact factor: 3.891
View more
  5 in total

1.  Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro.

Authors:  F G Hayden; A N Schlepushkin; N L Pushkarskaya
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

2.  Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, interferon, and bropirimine.

Authors:  D F Smee; J L Morris; J A Leonhardt; J R Mead; A Holy; R W Sidwell
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

3.  Broad-spectrum synergistic antiviral activity of selenazofurin and ribavirin.

Authors:  J J Kirsi; P A McKernan; N J Burns; J A North; B K Murray; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

Review 4.  Antiviral chemotherapy and prophylaxis of viral respiratory disease.

Authors:  S J Sperber; F G Hayden
Journal:  Clin Lab Med       Date:  1987-12       Impact factor: 1.935

5.  A Computationally Designed Hemagglutinin Stem-Binding Protein Provides In Vivo Protection from Influenza Independent of a Host Immune Response.

Authors:  Merika Treants Koday; Jorgen Nelson; Aaron Chevalier; Michael Koday; Hannah Kalinoski; Lance Stewart; Lauren Carter; Travis Nieusma; Peter S Lee; Andrew B Ward; Ian A Wilson; Ashley Dagley; Donald F Smee; David Baker; Deborah Heydenburg Fuller
Journal:  PLoS Pathog       Date:  2016-02-04       Impact factor: 6.823
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.